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ABSTRACT
A single tumor may contain cells with different
somatic mutations. By characterizing this genetic
heterogeneity within tumors, advances have been
made in the prognosis, treatment and understand-
ing of tumorigenesis. In contrast, the extent of
epigenetic intra-tumor heterogeneity and how it
influences tumor biology is under-explored. We
have characterized epigenetic heterogeneity within
individual tumors using next-generation sequen-
cing. We used deep single molecule bisulfite
sequencing and sample-specific DNA barcodes to
determine the spectrum of MLH1 promoter methyla-
tion across an average of 1000 molecules in each of
33 individual samples in parallel, including endome-
trial cancer, matched blood and normal endome-
trium. This first glimpse, deep into each tumor,
revealed unexpectedly heterogeneous patterns of
methylation at the MLH1 promoter within a subset
of endometrial tumors. This high-resolution analysis
allowed us to measure the clonality of methylation
in individual tumors and gain insight into the accu-
mulation of aberrant promoter methylation on both
alleles during tumorigenesis.
INTRODUCTION
Tumors are often genetically heterogeneous; a phenome-
non in which cells from the same tumor contain diﬀerent
sets of somatic mutations (1–3). The study of genetic het-
erogeneity can provide insight into the dynamics of tumor
development and the order in which mutations occur
during tumorigenesis (4,5). Tumor heterogeneity accounts
for a variety of clinically deﬁned phenotypes, including
outcome. In lung cancer and chronic myeloid leukemia,
resistance to kinase inhibitors is associated with expansion
of rare populations of cells that carry a drug resistant
second-site mutation in addition to the original activating
mutation (6–9). Signiﬁcantly higher risk for progression
to cancer is associated with greater mutation diversity
in Barrett’s esophagus, the premalignant precursor esoph-
ageal adenocarcinoma (10).
Epigenetic heterogeneity is likely to play a similarly
important role in tumor development and response to
therapy. Epigenetic mutations (epimutations) can pheno-
copy genetic mutations. Aberrant promoter methylation
and associated silencing of tumor suppressor genes can
provide a selective advantage to neoplastic cells (11).
In recent years, the signiﬁcance of epigenetic defects in
cancer biology has become evident. Aberrant DNA
methylation has been observed in all types of cancer
cells thus far examined and is frequently associated with
inappropriate transcriptional gene silencing (11).
However, intra-tumor heterogeneity of promoter methyla-
tion has only rarely been examined (12–15), in part due to
a lack of adequate technology. Therefore, we sought a
method that could sensitively characterize the heterogene-
ity of DNA methylation in many individual tumors in
parallel. Deep single molecule bisulﬁte sequencing using
next-generation machines has recently been applied to
sequence promoter methylation in cancer (14,16). Taylor
and colleagues’ seminal work demonstrated that disease-
speciﬁc tags and 454 sequencing can be used to identify
methylation patterns that diﬀer between types of leukemia
and lymphoma (16). Korshunova et al. (14) incorporated
sample-speciﬁc barcodes with 454 sequencing and found
complex methylation in breast cancer and sera DNA at
biomarker loci. We sought to adapt these methods to
obtain a high-resolution proﬁle of intra-tumor heteroge-
neity deep within individual tumors to begin to discern
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We focused our eﬀorts on characterizing MLH1 pro-
moter methylation heterogeneity in endometrial tumors.
Germline mutations in MLH1, a DNA mismatch repair
gene, result in hereditary colorectal and endometrial can-
cers with microsatellite instability (MSI) (17–19). Sporadic
endometrial cancers that have lost DNA mismatch
repair frequently exhibit promoter hypermethylation and
concomitant silencing of MLH1, leading to a mutator
phenotype, referred to as MSI in these tumors. Over
70% of MSI positive endometrial cancers have hyper-
methylation of the MLH1 promoter (20). MLH1 methyla-
tion is thought to be an early event in sporadic
microsatellite unstable endometrial cancer that contri-
butes to clonal expansion (21,22). MLH1 promoter
methylation is clearly a key event in the development
of many endometrial cancers; however, the spectrum
of MLH1 promoter methylation within individual
tumors has never been examined. Characterizing the het-
erogeneity of MLH1 promoter methylation for thousands
of single molecules in individual endometrial tumors will
provide more information about the timing and variability
of this event in tumor development.
MATERIALS AND METHODS
Sample acquisition, DNA extraction, bisulfite treatment
Endometrial tissue specimens and blood were obtained at
the time of surgery, snap frozen and stored at  708C (IRB
approval 93-0828). Tumors were histologically evaluated
to ensure high neoplastic cellularity for the tissues used for
DNA preparations. DNA was prepared using proteinase
K and phenol extraction or with the DNeasy Tissue Kit
(Qiagen Inc, Valencia, CA). DNA was extracted from
matched peripheral blood leukocytes as previously
described (23,24) or using DNeasy Tissue Kits (Qiagen
Inc, Valencia, CA). The quality of the genomic DNA
was assessed by measuring absorbance, and samples
were required to have an A260/280 ratio of 1.77–1.85 to
be included in the study. Genomic DNA was also ana-
lyzed on a 1% agarose gel to ensure that it was present
in high molecular weight fragments (>5kb). Genomic
DNA (250ng) from each of 33 samples was sodium bisul-
ﬁte treated in parallel using the EZ DNA Methylation-
Gold Kit (Zymo Research Corp, Orange, CA).
Amplicon design, PCR, FLX sequencing
Primers were designed to PCR amplify the 700-bp pro-
moter upstream of the MLH1 transcription start site
(Refseq NM_000249 UCSC Human Genome March
2006 Assembly http://genome.ucsc.edu/). PCR ampliﬁca-
tion was performed from each sodium bisulﬁte treated
DNA sample in two separate reactions, a Distal PCR
and a Proximal PCR. The Distal PCR primer sequences
were 50 AGTAGTTTTTTTTTTAGGAGTGAAGGAG
GTTA 30 and 50 CTTCTCAAACTCCTCCTCTCCCCT
TA 30. The Proximal PCR primer sequences were 50 TA
AGGGGAGAGGAGGAGTTTGAGAAG30 and 50 AA
AATACCTTCAACCAATCACCTCAATACCT 30.
The PCR was performed with primers speciﬁc to the
locus that were also tailed with a sample-speciﬁc DNA
barcode sequence and a 454 Life Sciences machine speciﬁc
primer (Supplementary Data 1). There are 1024 possible
5-bp DNA sequences, and we selected 33 sample-speciﬁc
barcodes, one for each sample, that did not contain homo-
polymers and had the least sequence similarity to each
other. The PCR for each locus in each sample was per-
formed in a total volume of 50ml. The reaction contained
1  PCR Buﬀer MgCl2 (Invitrogen, Carlsbad, CA), 10
units Platinum Taq Polymerase (Invitrogen Carlsbad,
CA), 0.5mM each dNTP, 1M Betaine, 0.5mM Forward
Primer, 0.5mM Reverse Primer and 125ng bisulﬁte treated
genomic DNA. This reaction was incubated at 938C for
2min, followed by (938C for 2min, 558C for 6min)   30
cycles, and held at 48C. One-ﬁfth of the PCR reaction for
each of 66 reactions was quantiﬁed by electrophoresis on a
2% agarose gel. This was achieved by quantitatively com-
paring the intensity of the gel band containing the PCR
product to the intensity of the similar size band in the Low
Molecular Weight DNA Ladder (NEB). The quantity of
PCR product is computed by dividing the PCR product
intensity by the scaling factor, which is the ladder band
intensity divided by the ladder band molecular weight.
Equimolar quantities of each PCR product were then
pooled into a single tube, puriﬁed on a Qiaquick column
(Qiagen Inc, Valencia, CA) and submitted to Cogenics
Inc. (www.cogenics.com) for sequencing on the 454 Life
Sciences FLX machine.
Cloning and Sanger sequencing
We cloned and sequenced 45 molecules from the distal and
proximal amplicons from both the endometrial cancer
sample and the matched normal blood from a single
patient for comparison between sequencing methods. To
clone the PCR products we ligated them into the pGEM-T
Easy Vector using Rapid Ligation Buﬀer according to the
manufacturer’s instructions (Promega, Madison, WI). We
then transformed the ligated vector into GC10 Competent
Cells (Gene Choice) and grew them overnight on LB-agar
(Luria-Broth) plates containing standard concentrations
of carbenicillin, X-gal and IPTG. After overnight
growth, colonies were picked from the plates and added
to 50ml colony PCR reactions containing 1  PCR
Reaction Buﬀer (Sigma, St Louis, MO), 1.25 units
Jumpstart Taq Polymerase (Sigma), 0.2mM each dNTP,
0.5mM M13 Forward Primer (50 CGCCAGGGTTTTCC
CAGTCACGAC 30), 0.5mM M13 Reverse Primer (50 TC
ACACAGGAAACAGCTATGAC 30) and 0.01% Tween.
The reaction was incubated at 948C for 10min, followed
by (948C for 1min 30s, 558C for 1min, 728C for
1min)  35 cycles and held at 48C. These reactions
were then treated with 10ml ExoSAP to degrade the
remaining primers and nucleotides by adding 0.2units
Exonuclease I (USB, Cleveland, OH) and 0.2units
Shrimp Alkaline Phosphatase (SAP) (Promega,
Madison, WI) in 1  SAP buﬀer (Promega, Madison,
WI), incubating at 378C for 30min, then heat inactivate
by incubating at 808C for 30min. The Sanger sequencing/
cycle sequencing reactions were 20ml and contained 1.5ml
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v3.1 RR-100 Mix (Applied Biosystems, Foster City, CA),
2mM MgCl2 and 0.16mM M13 Forward Primer. They
were incubated at 968C for 1min, followed by (968C for
10s, 508C for 5s, 608C for 4min)   24 cycles, and held at
48C. The reactions were ethanol precipitated with sodium
acetate and submitted to the Washington University
Genome Sequencing Center to load on the ABI 3730
(Applied Biosystems, Foster City, CA).
Sequence analysis
We obtained 180 reads from Sanger sequencing from the
distal and proximal regions in both the tumor sample and
normal blood sample of a single patient. To calculate the
correlation coeﬃcient between the results from the Sanger
sequencing and the FLX sequencing of the same samples
we ﬁrst calculated the percent of methylated reads at each
CG position in each sample and stored these values in a
vector. We then calculated the Pearson correlation coeﬃ-
cient between the vectors from the Sanger sequencing
results and the vectors from the FLX sequencing.
We obtained more than 33000 reads from FLX
sequencing that had perfect matches to either the distal
or proximal MLH1 promoter PCR primers. We deter-
mined which reads came from each sample based on
exact matches to a sample-speciﬁc DNA barcode that
was the ﬁrst ﬁve bases in each read. We created a com-
pletely methylated bisulﬁte treated reference sequence by
substituting a T for all C’s in the sequence that were not in
CG dinucleotides. We aligned all the reads from a partic-
ular sample and locus to the reference sequence using
CLUSTALW (25). We computationally extracted each
column in the multiple sequence alignment that had a C
in the reference sequence. We substituted a 1 for C, a 0 for
T and a 2 for any other base or a gap. We visualized this
matrix as an image using the Matlab (The Mathworks,
Natick, MA) software package.
MSI analysis, COBRA and mismatch repair protein
immunohistochemistry
MSI analysis was performed using ﬁve National Cancer
Institute consensus microsatellite markers (BAT25,
BAT26, D2S123, D5S346 and D17S250) as previously
described (26,27). Tumors were classiﬁed as microsatellite
stable if there was no evidence of MSI in any marker.
Tumors were designated as having high-level MSI
(MSI+) if aberrant marker alleles were identiﬁed in at
least two of the ﬁve consensus panel markers.
The COBRA method was used to evaluate methylation
of the MLH1 promoter (28). Brieﬂy, tumor DNA was
bisulﬁte converted using commercially available kits
(CpGenome DNA Modiﬁcation Kit, Intergen Company,
Purchase, NY and EZ DNA Methylation Gold Kit, Zymo
Research, Orange, CA) following manufacturers’ recom-
mended protocols. Target CpG-rich sequences in the
MLH1 promoter region were ampliﬁed using two
rounds of PCR. Restriction digest of PCR products was
then undertaken using enzymes that recognize sequences
potentially altered by methylation. PCR primers and
conditions, as well as restriction enzymes for this assay
have been previously published by our group (29).
Immunohistochemistry for MLH1, MSH2, MSH6
and PMS2 was performed using formalin-ﬁxed,
paraﬃn-embedded tissue sections. Tissues were stained
with antibodies to hMLH1 [clone G168 728; 1mg/ml
(Pharmingen)], hMSH2 [clone FE11; 0.5mg/ml
(Oncogene Science)], hMSH6 [clone 44, 0.5mg/ml
(Transduction Laboratories)] and hPMS2 (clone A16-4,
BD Pharmingen) as previously described by our group
(30). The expression status for each tumor was based on
nuclear staining in tumor cells. Tumors that lacked
nuclear staining but had normal positive staining in sur-
rounding non-neoplastic cells were classiﬁed as negative
for expression of the respective proteins.
RESULTS
Experimental design to measure intra-tumor heterogeneity
of MLH1 promoter methylation in endometrial cancer
To characterize the epigenetic heterogeneity at the MLH1
locus in endometrial tumors, we bisulﬁte treated genomic
DNA from 14 endometrial cancers, 14 matched bloods
and ﬁve normal endometrial tissue. To determine if deep
single molecule bisulﬁte sequencing could detect methyla-
tion that the COBRA (28) method could not, we
sequenced six tumors that were unmethylated according
to COBRA and eight tumors that were methylated
according to COBRA. We also included normal endome-
trial tissue from healthy control patients in this study to
determine the background level of MLH1 promoter
methylation by deep sequencing. To determine if we
could detect methylated tumor DNA in blood of indi-
viduals with endometrial cancer we included matched
blood samples.
Sodium bisulﬁte treatment converts unmethylated cyto-
sine into uracil while leaving methylated cytosine intact,
allowing us to determine the pattern of cytosine methyla-
tion by sequencing (Figure 1A) (31,32). We performed
PCR to amplify the desired loci from each sample.
Because the average read length on the 454 Life Sciences
Inc. FLX is  350bp, we separately ampliﬁed the distal
and proximal regions of the 700bp promoter upstream
of the MLH1 transcription start site (RefSeq #
NM_000249). It has previously been shown that methyla-
tion within this region of the promoter is correlated with
gene expression; a 70bp section in the proximal promoter
at  209 to  139bp relative to the transcriptional start site
(Refseq NM_000249 UCSC Human Genome March 2006
Assembly) was particularly well correlated (33). The locus-
speciﬁc PCR primers were tailed at the 50 end with sample-
speciﬁc DNA barcodes and 454 sequencing primers
(Figure 1B). Equimolar quantities of each PCR product
were pooled in a single tube (N=66, two amplicons for
each of 33 starting templates) and sequenced from both
ends using 454 FLX sequencer (Figure1C). More than
33000 reads were obtained. The ﬁrst ﬁve bases of each
sequence are sample-speciﬁc barcodes that indicate the
sample of origin and the remaining bases reveal the
Nucleic Acids Research, 2009,Vol.37, No. 14 4605methylation status of the DNA molecule, as well as any
SNPs in the sequence.
Comparison to conventional Sanger sequencing
The standard method for determining methylation pat-
terns on single molecules is bisulﬁte treatment followed
by cloning and Sanger sequencing. Single molecule PCR
methods (34,35) have been recently introduced as simpli-
ﬁed workﬂow and to mitigate cloning bias. We compared
the methylation patterns obtained using the standard
method to those obtained using deep single molecule
sequencing on second-generation sequencing machines.
We cloned bisulﬁte-treated DNA ampliﬁed from the
tumor and matched blood of a single patient (Patient
#1684) and Sanger sequenced 45 clones from both the
distal and proximal region of the promoter (Figure 2A).
Results for conventional sequencing analysis were com-
pared to the 454 FLX sequencing of the same samples,
comprising 496 reads from the distal region of the
MLH1 promoter and 480 reads from the proximal
region (Figure 2B). The 454 FLX sequencing and Sanger
sequencing results were nearly identical. To quantify the
similarity between the results from the two methods we
calculated the percent of cytosines methylated at each CG
in each sample and determined the correlation coeﬃcient
for the two analytic approaches. The methods produce
highly similar methylation patterns (R
2=0.96). Both
methods revealed the majority of tumor DNA molecules
from the MLH1 promoter were densely methylated. A
small percentage of molecules in the tumor were unmethy-
lated. These unmethylated sequences are likely derived
from normal non-neoplastic cells in the tumor. The neo-
plastic cellularity (NPC) of tumor 1684 was estimated to
be 70% based on histological assessment of the tissue used
for DNA preparation. Both 454 FLX and Sanger sequenc-
ing revealed dense methylation of the proximal promoter
Figure 2. Comparison of sequencing results from conventional cloning
and Sanger sequencing and 454 Life Sciences FLX sequencing
of MLH1 promoter PCR products from bisulﬁte treated DNA of
an endometrial cancer and normal blood from Patient #1684. (A)
Schematic of the MLH1 promoter is presented with arrows indicating
the location of PCR primers and vertical lines representing the position
of CG dinucleotides. Below the schematic are the results from cloning
and bisulﬁte sequencing 45 molecules from the distal (left) and proxi-
mal (right) promoter in each sample (tumor and matched normal
blood). Each column represents a CG dinucleotide in the sequence,
and corresponds to each vertical line in the promoter schematic.
Each row represents a single molecule. The color of the boxes repre-
sents the methylation state of each cytosine. Red, methylated; Black,
unmethylated. (B) The results from the FLX single molecule sequencing
of the same samples. The distance of each CpG from the transcription
start site (UCSC Human Genome March 2006) is listed from distal
to proximal. The Distal Amplicon:  671,  662,  654,  648,  634,
 632,  630,  626,  623,  619,  609,  605,  596,  584,  576,
 569,  566,  564,  560,  558,  548,  540,  537,  512,  505,
 483,  470,  465,  449,  446,  421,  405,  380,  368. The
Proximal Amplicon:  341,  325,  318,  286,  280,  249,  240,
 226,  209,  202,  192,  190,  184,  165,  154,  139,  70,  47,
 23,  15. As an additional point of reference, the translation start site
(ATG) is currently annotated at +60 downstream of the transcription
start site (position 0).
Figure 1. Experimental design for deep bisulﬁte sequencing in indi-
vidual samples. (A) Detection of DNA methylation by sodium bisulﬁte
treatment and PCR. (B) PCR ampliﬁcation with sample speciﬁc DNA
barcodes. (C) Pool PCR products for 454 sequencing.
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The normal blood from Patient #1648 was unmethylated
in the MLH1 promoter as assessed by both 454 FLX and
Sanger sequencing (Figure 2A). We found that >99% of
non-CpG cytosines were converted in each sample, indi-
cating the sodium bisulﬁte conversion was successful.
The similarity between the Sanger and FLX sequencing
for this patient’s samples conﬁrmed that the FLX sequenc-
ing strategy can be used to bisulﬁte sequence single mole-
cules in individual samples in high-throughput.
MLH1 promoter methylation in MLH1 deficient
endometrial tumors is heterogeneous
Tumors lacking MLH1 mismatch repair activity have
either loss-of-function mutations or epigenetic silencing
of MLH1(17,18,20–22). We studied nine MSI-positive pri-
mary endometrial cancers that lacked MLH1 expression
based on immunohistochemical evaluation. Eight of nine
tumors had methylation of the proximal MLH1 promoter
based on COBRA (28,36) (Table 1). An accepted model of
endometrial tumorigenesis is that a single somatic cell
acquires dense promoter methylation with the inactivation
of MLH1. The inactivation confers a selective advantage
to the cell. The cell then undergoes a clonal expansion,
propagating the aberrant MLH1 promoter methylation
through division (37,38). Therefore we expected to observe
a homogeneous population of densely methylated MLH1
promoter molecules in these tumors.
In four of eight of the MLH1 methylated tumors ana-
lyzed, we observed the expected dense homogeneous
methylation (Table 1). For example, the tumor from
patient #1569 is densely methylated at all CpGs in both
the distal and proximal regions of the MLH1 promoter
(Figure 3A). In tumors 1569, 1669, 1727 and 1789, dense
MLH1 promoter methylation appears to have been an
early event propagated throughout the tumor during the
subsequent clonal expansion.
In four of eight of the MLH1 methylated tumors
analyzed, we observed heterogeneity in the pattern of
methylation across the molecules within individual
tumors (Figure 3C, D, E and F). For example, we
observed two distinct patterns of methylation in the
distal region of the MLH1 promoter in tumor of Patient
#1495 (Figure 3C). Although the distal promoter is heav-
ily methylated,  20% of the methylated molecules exhibit
a distinct alternating (checkerboard) pattern of unmethy-
lated CpGs. The distinct pattern of methylation for a sub-
population of sequences indicates that the tumor is not
clonal for methylation. Because demethylation is believed
to be a rare event (39,40), the pattern of alternating
methylated and un-methylated CpGs likely resembles the
methylation state in the initiating tumor cell. The observed
heterogeneity could be explained by expansion of this ini-
tial tumor cell followed by methylation of additional
CpGs along certain lineages. Interestingly, the four
tumors that were identiﬁed as having heterogeneous pat-
terns of methylation were from younger women with ear-
lier stage disease compared to the four cases with
homogeneous patterns of MLH1 methylation (Table 1).
Each tumor that displayed epigenetic heterogeneity at
the MLH1 locus had a unique signature of methylation.
Heterogeneity occurred in either the distal region
(Figure 3C and E) or in the proximal promoter region
(Figure 3D and F). All four tumors with heterogeneous
methylation do not express MLH1 as assessed by IHC
(Table 1). Although the same set of CpGs are not methy-
lated in every tumor, all of the tumors have >50% of CpG
positions methylated at this locus. These data support
the model, proposed by others, that it is the degree of
methylation across the molecule rather than site-speciﬁc
methylation that is associated with gene silencing (41–44).
Table 1. Comparison of FLX bisulﬁte sequencing to traditional measurements in endometrial cancer tumor samples
Tumor
sample no.
Percent of methylated
molecules in
proximal promoter
COBRA MSI MLH1 IHC NPC (%) Age Stage Grade Heterogenous
methylation
patterns
1499 0 u   + 90 77.53 IA 1 –
1472 0 u   + 85 62.02 IB 1 –
1487 0 u   + 100 81.12 IB 1 –
1556 0 u   + 70 82.55 IVB 1 –
1673 0 u   + 75 74.5 IVB 1 –
1758 0 u +   60 59.47 IB 3 –
1645 15 m +   80 61.47 IC 2 Y
1789 48 m + + 90 61.52 IVB 2 N
1727 49 m +   75 75.58 IC 1 N
1576 54 m +   70 55.91 IC 2 Y
1495 59 m +   70 49.96 IIA 1 Y
1669 65 m +   80 90.73 IVB 3 N
1569 77 m +   85 81.05 IIIA 1 N
1684 86 m +   >70 72.32 IB 1 Y
FLX bisulﬁte sequencing was summarized by calculating the fraction of molecules from the proximal promoter with >50% of CpGs methylated.
COBRA is reported as u, unmethylated; m, methylated; MSI, Microsatellite Instability is reported as  , stable; +, unstable; MLH1 IHC, MLH1
protein immunohistochemistry; NPC (%), estimated neoplastic cellularity by microscopy. The age of the patient at diagnosis as well as the stage and
grade of the tumor are listed in columns 7–9. Shading distinguishes classes of tumors; Grey, unmethylated, active MLH1; White, unmethylated,
inactivated MLH1; Red, methylated. The presence of heterogeneous patterns of methylation within the tumor is indicated by a Y in the last column,
absence of heterogeneity is indicated by an N.
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cancer patient blood, healthy control endometrial
tissue and MLH1 expressing tumors
Since deep single molecule bisulﬁte sequencing provides
the opportunity to detect rare methylated molecules and
methylation at sparse CpGs across a locus, we examined if
we could detect methylation in 14 matched endometrial
cancer patient blood samples, ﬁve healthy control endo-
metrial tissues and six MLH1-expressing tumors. Even
with deep bisulﬁte sequencing, we did not detect DNA
methylation in any of these samples.
Allelic promoter methylation
We next asked if diﬀerent alleles of the MLH1 promoter
displayed diﬀerent patterns of methylation. Four of the
methylated tumor samples were heterozygous for a SNP
(rs1800734) in the proximal promoter region of MLH1,
allowing us to identify the pattern of methylation for each
allele (Figure 4). All four tumors have dense methylation
on both alleles in near equal fractions, even when only
a subclone of the tumor is methylated (Supplementary
Table 1). The tumor sample from patient #1576 has
a heterogeneous pattern of methylation in the proximal
promoter, with distinct patterns of methylation evident
for the two alleles. If the heterogeneous pattern of methy-
lation arose randomly, both MLH1 alleles would be
expected to show the heterogeneous pattern of methyla-
tion. Alternatively, if the patterns start in an initiating
tumor cell and methylation accumulates as the tumor
divides and expands, then the alleles should maintain
their distinct patterns. Our data indicate that
Figure 3. Representation of the diﬀerent types of methylation observed in endometrial cancer specimens. The numerical patient identiﬁer is followed
by the bisulﬁte sequencing results for the distal and proximal MLH1 promoter in the tumor. (A) Methylated molecules from a tumor with dense
homogenous promoter methylation. (B) Homogenous tumor with no promoter methylation. (C) and (E), Methylated molecules from tumors with
distinct heterogeneous patterns of unmethylated cytosines in distal promoter. (D) and (F), Methylated molecules from tumors with distinct heter-
ogeneous patterns of unmethylated cytosines in proximal promoter. Completely unmethylated molecules from the tumors in A, C, D, E and F were
not included to allow for better resolution of the methylation patterns. Each column represents a CG dinucleotide. Each row represents a single
molecule. The color of the boxes represents the methylation state of each cytosine. Red, methylated; Black, unmethylated.
4608 Nucleic Acids Research, 2009, Vol. 37,No. 14heterogeneous patterns diﬀer between alleles suggesting
the allelic methylation patterns are stably inherited
(Figure 4C).
Comparison of 454 sequencing to standard assays
Traditional bulk assays of the molecular characteristics of
tumors have enabled the classiﬁcation of tumors into sub-
types. We compared our high resolution methylation mea-
surements to the results from the traditional COBRA
method for these tumors. We found that MLH1 promoter
methylation existed in two states, unmethylated or densely
methylated, so we summarized our data by calculating
the fraction of molecules from the proximal promoter
with greater than 50% of CpGs methylated. As seen in
Table 1, our metric correlates with the COBRA methyla-
tion status, MLH1 expression and MSI. A notable excep-
tion is patient 1758 whose tumor is unmethylated
(according to both assays), but is not expressing MLH1
and is MSI+. This ﬁnding suggests another mechanism of
MLH1 inactivation, possibly mutation. None of
the patients in this study had recognized hereditary
non-polyposis colorectal cancer (HNPCC), so further
investigation is needed to identify the somatic mutations
responsible for this loss of MLH1.
Since biallelic MLH1 promoter methylation is thought
to be an early event during tumorigenesis, all tumor cells
would be expected to contain methylated molecules.
Therefore, the fraction of methylated molecules is likely
to represent the DNA in the sample that is from neoplastic
cells. Unmethylated molecules, on the other hand, are
likely derived from adjacent or inﬁltrating normal cells.
We compared the fraction of molecules that were densely
methylated with the neoplastic cellularity estimated by
light microscopy of tumor tissues. We found one notable
discrepancy between the measures (Table 1). In the tumor
from Patient #1645, only 15% of the sequenced molecules
are densely methylated, but the neoplastic cellularity was
estimated to be 80%. In this case the 15% of molecules
that are methylated may represent a distinct subclone in
the tumor that has acquired aberrant promoter methyla-
tion. This methylation appears on both alleles in near
equal fractions (18% of the molecules from the A allele
and 11% of the molecules from the G allele) indicating
both alleles were methylated in the subclone of the tumor.
Under this scenario, it is assumed that a diﬀerent tumor
initiating event caused MLH1 to be silenced, resulting in
an MSI+ tumor. This patient’s family history of cancer
included a sister with endometrial cancer and other most
distantly related family members with cancers. Although
her history does not fulﬁll the established clinical criteria
for HNPCC, it is likely that she had an inherited cancer
susceptibility and that her tumor was caused by mutation
of MLH1. The observed methylation in her tumor is con-
sistent with recent reports in colorectal cancer that rare
methylation events can be found in cancers caused by
germline mutations (45). The sensitive resolution of the
deep single molecule bisulﬁte sequencing made it possible
to discover this exceptional case, a tumor that is polyclo-
nal for MLH1 promoter methylation.
Evaluation of PCR Bias
The biased ampliﬁcation of certain molecules during PCR
could result in a small number of template molecules gen-
erating the bulk of the sequencing reads. The presence of
PCR bias would prevent the accurate assessment of intra-
tumor heterogeneity. There are two complimentary meth-
ods to evaluate whether sequencing reads were generated
from a biased PCR ampliﬁcation of a limited number
of template molecules or whether sequencing reads were
generated from diverse template molecules and are repre-
sentative of the sample. First, for samples that are hetero-
zygous for a SNP, if one template molecule is ampliﬁed
preferentially then the ratio of reads from each allele
would deviate from the expected 50%. Four of the
patients we evaluated were heterozygous for a SNP in
the proximal promoter. For each patient we counted the
number of reads from each allele. In each sample, the
fraction of reads from the A allele is: 1495 47%, 1569
56%, 1576 50%, 1645 50%. These results indicate an
absence of PCR bias, since each alleles is represented
at the expected frequency (50%). The second way to deter-
mine if particular template molecules are overrepresented
in the sequencing reads is to examine the patterns of cyto-
sines in the sequence. Since the sodium bisulﬁte conversion
Figure 4. Patterns of methylation for diﬀerent MLH1 alleles.
Methylated sequences from the proximal MLH1 promoter in four
tumors heterozygous at the rs1800734 SNP are presented. Both
alleles are methylated in all four patient’s tumors. (A) Patient 1495.
(B) Patient 1569. (C) Patient 1576, this tumor displays heterogeneous
patterns of methylation that are distinct on the two alleles, suggesting
the allelic patterns are inherited as the tumor divides. (D) Patient 1645.
Completely unmethylated molecules from these tumors are excluded
from these graphs for better resolution of methylation patterns. Each
column represents a CG dinucleotide or the SNP. Each row represents
a single molecule. The color of the boxes represents the methylation
state of each cytosine. Red, methylated; Black, unmethylated. The posi-
tion of the SNP in the sequencing reads is indicated by the green and
blue column. The color of the box indicates the base at that position,
Blue, A allele; Green, G allele.
Nucleic Acids Research, 2009,Vol.37, No. 14 4609of the samples in this study was  99% eﬃcient, some
cytosines in individual template molecules were not con-
verted, giving some molecules unique patterns of uncon-
verted cytosines. If PCR bias occurs then the patterns
of cytosines in the sequencing reads would be clonal.
In contrast, if the sequencing reads originate from diverse
molecules, then we expect to see diverse patterns of uncon-
verted cytosines. To analyze the diversity of cytosine pat-
terns in the sequencing reads, we determined the fraction
of reads that contained at least one cytosine. These are the
reads that we can evaluate for diversity or clonality. We
next calculated the fraction of reads with cytosines that
have a unique pattern (Supplementary Table 2). We found
that, in each sample, greater than 93% of the reads with
cytosines had distinct patterns. Thus, we concluded that
our sequencing reads were generated from a diverse pool
of starting molecules.
DISCUSSION
We used deep single molecule bisulﬁte sequencing and
sample-speciﬁc DNA barcodes to reveal the spectrum
of MLH1 promoter methylation across an average
of 1000 molecules in each of 33 individual samples in
parallel, including endometrial cancer, matched blood
and normal endometrium. This high-resolution analysis
allowed us to measure the clonality of methylation in
tumors and gain insight into the accumulation of aberrant
promoter methylation during tumorigenesis.
MLH1 promoter methylation is a tumor initiating
event in sporadic MSI+ endometrial cancers. As such,
the MLH1 promoter methylation is expected to be uni-
form and dense throughout these tumors. Deep single
molecule bisulﬁte sequencing revealed unexpected hetero-
geneous patterns of MLH1 promoter methylation within
individual tumors. This intra-tumor heterogeneity was
found in half (four out of eight) of the tumors that were
methylated at the MLH1 promoter. We observed distinct
patterns of methylation in which promoter molecules were
densely methylated, but with diﬀerent sets of CpGs methy-
lated. The patterns of methylation found in each hetero-
geneous tumor allow us to hypothesize as to how DNA
methylation accumulated. Because DNA demethylation is
thought to be rare (39,40), heterogeneous patterns of
methylation are likely attributable to gains in methylation
rather than losses. The promoter sequences with the least
(fewest) CpG methylation events likely represent the
methylation pattern most similar to the one present in
the tumor initiating cell. As the tumor divides, the pattern
of methylation would be propagated and certain lineages
in the tumor would accumulate additional methylation.
Each of the four tumors with epigenetic heterogeneity
displayed distinct patterns of methylation, suggesting
that each tumor was initiated with a diﬀerent pattern of
methylation in the MLH1 promoter. Four MLH1
methylated endometrial tumors were heterozygous for a
SNP (rs1800734) in the MLH1 promoter, allowing us to
examine allele-speciﬁc methylation. We observed dense
methylation on both alleles in each of the four samples.
The methylation was present on both alleles in equal
fractions of the reads, even when the methylation was a
late event in Patient 1645 (Supplementary Table 1). This
suggests that both alleles are methylated at the same time
and the methylation is propagated in the subclone of the
tumor. One tumor exhibited distinct patterns of methyla-
tion on each allele. This pattern supports the model that
once the alleles are methylated, the methylation pattern
can be stably inherited throughout the expansion of the
tumor. Further development of the methods described
herein to enable high-throughput bisulﬁte sequencing
from microdissected tumor cells would allow one to test
this model.
Using next-generation sequencing to assess intra-tumor
epigenetic heterogeneity we identiﬁed a new molecular
subclass of MSI+ endometrial cancers: tumors with
heterogeneous MLH1 promoter methylation. Follow-up
studies are needed to determine if classiﬁcation of
tumors based on their epigenetic heterogeneity can be
used to stratify disease subtypes with distinct prognosis
or responses to treatment. It will be important to have
high-throughput methods, such as the one described
here, to identify tumor subclasses that are deﬁned by dis-
tinct epigenetic defects.
High-throughput deep sampling of methylation in indi-
vidual tumors aﬀords new opportunities for modeling
tumorigenesis. Analysis of multiple loci from a single
tumor, including neutral loci, will provide the opportunity
to apply the mathematical framework of population
genetics to analyze tumor development and evolution, as
in the pioneering work of Shibata, Nowak and colleagues
(46–50). This will be useful for determining the frequency,
timing and order of aberrant methylation events during
tumorigenesis.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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